NCT07018544

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea.

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 840 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: —

Summary

This study is conducted to investigate the safety and effectiveness of semaglutide in participants with obesity and overweight in routine clinical practice. Participants will get semaglutide as prescribed by a doctor. This study will last for about 4 years and participants will participate in the study for approximately 26 weeks.

Conditions

• Obesity and Overweight

Interventions

Type	Name	Description
OTHER	semaglutide	Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Timeline

• Start date: 2024-11-19
• Primary completion: 2027-02-28
• Completion: 2027-02-28
• First posted: 2025-06-12
• Last updated: 2025-06-12

Locations

8 sites across 1 country: South Korea